Evidence map›Paper›PMID 27102893›Full record

ReviewGene2016

Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1).

Wanhong He, Misra Gauri, Tang Li, Ruixuan Wang, Sheng-Xiang Lin

Open access · greenAbstract readReview
In one paragraph

Review in Gene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. MTHFR as a Novel Candidate Marker for Litter Size in Rabbits.Animals : an open access journal from MDPI · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Wanhong HeShanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai 200032, China.
Misra GauriAmity Institute of Biotechnology, Amity University, Noida, UP, India.
Tang LiLaboratory of Endocrinology and Oncology, CHU de Québec Research Center and Laval University, Canada.
Ruixuan WangLaboratory of Endocrinology and Oncology, CHU de Québec Research Center and Laval University, Canada.
Sheng-Xiang LinShanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai 200032, China; Laboratory of Endocrinology and Oncology, CHU de Québec Research Center and Laval University, Canada.
Université Laval · CAAmity University · INShanghai University of Medicine and Health Sciences · CN

Funding

The Gene Wiki: Community intelligence applied to gene annotationR01GM089820 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI SU, ANDREW I · 2010 to 2021
$5.2M
NIGMS NIH HHS R01 GM089820
6 · The paper itself

Abstract

At the late 1940s, 17β-HSD1 was discovered as the first member of the 17β-HSD family with its gene cloned. The three-dimensional structure of human 17β-HSD1 is the first example of any human steroid converting enzyme. The human enzyme's structure and biological function have thus been studied extensively in the last two decades. In humans, the enzyme is expressed in placenta, ovary, endometrium and breast. The high activity of estrogen activation provides the basis of 17β-HSD1's implication in estrogen-dependent diseases, such as breast cancer, endometriosis and non-small cell lung carcinomas. Its dual function in estrogen activation and androgen inactivation has been revealed in molecular and breast cancer cell levels, significantly stimulating the proliferation of such cells. The enzyme's overexpression in breast cancer was demonstrated by clinical samples. Inhibition of human 17β-HSD1 led to xenograft tumor shrinkage. Unfortunately, through decades of studies, there is still no drug using the enzyme's inhibitors available. This is due to the difficulty to get rid of the estrogenic activity of its inhibitors, which are mostly estrogen analogues. New non-steroid inhibitors for the enzyme provide new hope for non-estrogenic inhibitors of the enzyme.

Indexed as

AndrogensAnimalsEstradiol DehydrogenasesEstrogensHumansMutationNeoplasmsOrgan SpecificityAndrogensEstradiol DehydrogenasesEstrogensHSD17B1 protein, human17β-hydroxysteroid dehydrogenase (17β-HSD)Breast cancerDual sex-hormone modulationEstrogen dependent diseaseHigh activity in estrogen synthesisNarrow binding tunnel

Identifiers

PMID27102893
PMCPMC6649686
OpenAlexW2341657058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.